Q2 electric boogaloo3 Apr 2026 17:56
1)The Company is also progressing advanced late stage discussions regarding an additional clinical trial collaboration and will update the market in due course.
2)The Company also continues to move forward with its TrialSetβ’ vertical, which is being deployed into agreed-upon sites with ICON plc for an ongoing, mid-stage immunology and inflammation clinical trial sponsored by Takeda. Trellus is also implementing TrialSetβ’ with PSI Inc. across two late-stage immunology and inflammation clinical trials sponsored by Sanofi and will be deployed into agreed-upon sites beginning mid-Q2.
3)The collaboration with J&J, initially signed in January 2025, has been extended to mid-2026 with the same economic terms, including a fixed monthly management fee. A key factor in the extension was the achievement of engagement and satisfaction metrics during the initial pilot phase. Based on these metrics, J&J broadened the way patients can access the enrolment channels beyond the initial pilot funnel in mid-January 2026, reflecting continued confidence in the programme's performance.